In KRASG12C mutant tumor cells, Aurora-A facilitates the interaction between KRAS and C-RAF and is associated with adaptive reactivation of KRAS after KRASG12C inhibitor treatment.290 Combination of an Aurora-A inhibitor and a KRASG12C inhibitor shows synergistic effect in vitro and in vivo. The gene discussed is KRAS; the disease is neoplasm.